Xilio Therapeutics, Inc. XLO
Set alert
8.75 USD +0.76 +9.51%
As of Nov 3, 12:16 PM ET
7.94 Day range 8.85
7.14 52-week range 11.90
- YTD
- -2.34%
- 1 year
- -26.47%
- Open
- 7.94
- Prev close
- 7.99
- Mkt cap
- 58.20M
- Vol
- 13.73K
- Avg vol
- 12.22K
- EPS
- -0.60
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.94
- High
- 8.85
- Forward P/E
- -1.91
- Beta
- -0.20
- Short ratio
- 0.42
- Inst. own
- 29.50%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 1.01
- 200-d avg
- 0.970715
- 1y target
- 4.50
Analyst view
Consensus: buy
Buy
Price target (mean) 4.50 -48.6% downside
Now 8.75
- Target (low)
- 4.00
- Target (mean)
- 4.50
- Target (high)
- 5.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 3
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.24 | -0.24 – -0.24 | -0.64 | +62.5% | 0 | 0.0% | 1 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Current year | -1.21 | -1.21 – -1.21 | -2.78 | +56.5% | 7.69M | 0.0% | 1 |
| Next year | -0.67 | -0.67 – -0.67 | -1.21 | +44.6% | 36.07M | +368.7% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2024 | Raymond James | Maintained | Outperform | Outperform |
| May 30, 2023 | Chardan Capital | Reiterated | Buy | Buy |
| May 11, 2023 | Chardan Capital | Reiterated | — | Buy |
| Jan 27, 2023 | Morgan Stanley | Maintained | — | Overweight |
| Dec 21, 2022 | Chardan Capital | Initiated | — | Buy |
| Nov 10, 2022 | Raymond James | Maintained | — | Outperform |
| Aug 10, 2022 | Morgan Stanley | Maintained | — | Overweight |
| Jan 10, 2022 | HC Wainwright & Co. | Initiated | — | Buy |
| Nov 16, 2021 | Raymond James | Initiated | — | Outperform |
| Nov 16, 2021 | Cowen & Co. | Initiated | — | Outperform |
| Nov 16, 2021 | Morgan Stanley | Initiated | — | Overweight |